GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sensorion SA (XPAR:ALSEN) » Definitions » Unpaid Loss & Loss Reserve

Sensorion (XPAR:ALSEN) Unpaid Loss & Loss Reserve


View and export this data going back to 2015. Start your Free Trial

What is Sensorion Unpaid Loss & Loss Reserve?

Unpaid Loss & Loss Reserve only applies to insurance companies.


Sensorion Business Description

Traded in Other Exchanges
Address
375, rue du Professeur Joseph Blayac, Montpellier, FRA, 34080
Sensorion SA is a France-based clinical-stage biotech company dedicated to developing therapies to restore, treat, and prevent hearing loss. The company's product is in phase 2a clinical development, SENS-401 (Arazasetron) in Sudden Sensorineural Hearing Loss (SSNHL). SENS-401 is being developed to treat cochlear pathologies. The Company does business in a single operating segment: conducting research and development to discover drugs to treat inner ear disorders with a view to their future marketing. The company's pipeline programs are SENS-401 SSNHL, SENS-401 CIO, GJB2-GT, GJB2-GT, SENS-401 Cochlear, and others.